This week, the overall grades of 5 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Vanda Pharmaceuticals Inc. (VNDA) drops from a C to a D rating. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets F’s in earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

Stemline Therapeutics, Inc. (STML) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of STML stock.

This week, Cerulean Pharma, Inc.’s (CERU) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CERU stock.

Aptose Biosciences Inc. (APTO) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APTO stock.

This is a rough week for BIND Therapeutics, Inc. (BIND). The company’s rating falls to F from the previous week’s D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BIND stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.